Kare-In-Home Hospice Successfully Adopts Medalogix Muse

NASHVILLE, Tenn., Dec. 7, 2021 /PRNewswire/ -- Kare-In-Home Hospice of Gulfport, Mississippi adopts Medalogix Muse's machine learning tool to deliver an increased level of personalized care to their patients. The Medalogix Muse technology evaluates and models every clinical assessment,...

from PR Newswire: https://ift.tt/3Dz2ZpX

NavVis adds fresh funding to fulfill its mission to digitize commercial buildings and assets

The funding complements NavVis's recent debt funding from the European Investment Bank to solidify its technological leadership position, leveraging its momentum fueled by the need for up-to-date digital twins in construction, industry 4.0, and new trends such as the metaverse. MUNICH,...

from PR Newswire: https://ift.tt/3EvD2ZO

Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19

Funding comes through the Covid-19 Therapeutics Accelerator, which was set up by Wellcome, Bill & Melinda Gates Foundation and Mastercard TOKYO and CAMBRIDGE, United Kingdom, Dec. 7, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) today announced it has received...

from PR Newswire: https://ift.tt/302qcTH

Reacción de los clientes si las empresas no toman medidas contra el cambio climático

Las empresas de todo el mundo podrían enfrentarse a la reacción de sus clientes si no toman medidas contra el cambio climático Un nuevo estudio mundial examina las actitudes y comportamientos de todo el mundo respecto a la sostenibilidad y cómo esto podría redefinir las estrategias de...

from PR Newswire: https://ift.tt/3DusngE

Ionis and AstraZeneca to develop and commercialize eplontersen

CARLSBAD, Calif., Dec. 7, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced it has entered into a strategic collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis' investigational...

from PR Newswire: https://ift.tt/3oxwjbW

Le 4e produit biologique de Henlius : le biosimilaire du Bevacizumab Hanbeitai approuvé par l'Administration nationale des Produits Médicaux

SHANGHAI, 7 décembre 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) a annoncé que le Biosimilaire du Bevacizumab Hanbeitai, développé et fabriqué par Henlius de manière indépendante, a été approuvé par l'Administration nationale des produits médicaux (NMPA). Il est indiqué...

from PR Newswire: https://ift.tt/3EvM3lC

Henlius' 4. Biologics: Bevacizumab-Biosimilar Hanbeitai von der National Medical Products Administration genehmigt

SHANGHAI, 7. Dez. 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) gab bekannt, dass das Bevacizumab-Biosimilar Hanbeitai, welches von Henlius unabhängig entwickelt und hergestellt wird, von der National Medical Products Administration (NMPA) zugelassen wurde. Es ist für die...

from PR Newswire: https://ift.tt/3dpKpG6